Photo of Bexis

In our two prior posts concerning Bartlett v. Mutual Pharmaceutical Co., 678 F.3d 30 (1st Cir. 2012), we first hoped that the defendant would “take it up” to the Supreme Court, and ended our second with our belief that Bartlett was worthy of summary reversal.  Well, that happened earlier this week, and in the petition for certiorari, the defendants did indeed ask the court to consider summary reversal.
Rather than repeat the excellent summary on the FDA law blog, we’ll simply link to it.